News

Boston Therapeutics IpoxynTM Data to be Presented Today at Symposium at Massachusetts General Hospital

Boston Therapeutics IpoxynTM Data to be Presented Today at Symposium at Massachusetts General Hospital

Download PDF

MANCHESTER, N.H.--(BUSINESS WIRE)--Boston Therapeutics, Inc. (BTI), a public company registered with the SEC and a developer of diabetes therapeutics, announced today that experiments performed in the laboratory of Massachusetts General Hospital (MGH) faculty member Warren M. Zapol, MD, Emeritus Anesthetist-in-Chief and Director of the MGH Anesthesia Center for Critical Care Research, on BTI's new oxygen carrier for traumatic shock and ischemia, IPOXYNTM, will be presented at the "XIII International Symposium on Blood Substitutes and Oxygen Therapeutics" to be held July 27th-29th at MGH. Data will be presented in a talk by Binglan Yu, Ph.D., Instructor in Anesthesia, MGH, and will include hemodynamic data in a diabetic mouse model infused with IPOXYNTM.

"We are very pleased to have recently signed a Material Transfer Agreement with MGH to continue the animal testing of IPOXYNTM," said Ken Tassey, President, Boston Therapeutics. “IPOXYNTM is an oxygen carrier designed for critical limb ischemia associated with diabetes and we are excited to have this new data presented here today. We are preparing to scale-up our manufacturing of IPOXYNTM and our meetings with the FDA have shown positive support" said Tassey.

IPOXYNTM is a glyco-protein oxygen carrier designed for hypoxic conditions such as limb ischemia, hemorrhagic shock and other conditions requiring oxygen transport to hypoxic tissues. Using a proprietary carbohydrate chemistry platform, BTI has engineered a uniquely-stabilized oxygen carrier that has been shown to perfuse and selectively off-load oxygen in ischemic capillaries where the limb vasculature is damaged. IPOXYNTM is intended as a user-ready, intravenous solution to target acute hypoxic conditions that have a great unmet medical need.

“These new data from Drs. Yu and Zapol will add to our existing research on IPOXYNTM," said Joan Sellers, Ph.D., Chief Technology Officer, Boston Therapeutics. "In addition to lower limb ischemia, we anticipate the future indications for IPOXYNTM to include traumatic blood loss, anemia, hemorrhagic shock, as well as blood supplementation during surgery. We believe that IPOXYNTM will be a first-in-class drug upon FDA approval and we look forward to our continued collaboration with Dr. Zapol's laboratory at MGH," said Sellers.

About Boston Therapeutics, Inc.

Boston Therapeutics is a leader in the field of glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: IPOXYNTM, an IV-ready, oxygen carrier for hypoxia, PAZ-320, a diabetes drug candidate to reduce postprandial glucose excursions, and SUGARDOWN™, a complex carbohydrate-based dietary supplement to moderate post-meal blood glucose for pre-diabetes. The Company is headquartered in Manchester, NH. Additional information is available at www.bostonti.com.

IPOXYN™ and SUGARDOWN™ are registered trademarks of Boston Therapeutics, Inc.